We are pleased to announce that Lucid Health Consulting has been appointed by  Tryptamine Therapeutics Limited to manage the registration and develop a comprehensive reimbursement strategy for their innovative treatment, TRP-8803, (IV-infused psilocin), in Australia.

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Tryptamine Therapeutics intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field.

Our engagement by Tryptamine Therapeutics Limited will commence on July 1, 2024. We will advance product registration and reimbursement opportunities for TRP-8803 in the Australian market, including ongoing interactions with the Therapeutic Goods Administration (TGA).

To find out further details please refer to Tryptamine Therapeutics Limited ASX announcement, dated 19 June 2024 DOWNLOAD HERE and/or contact our Partner & Director George Papadopoulos using the following contact details.






+61 2-8964 9600


Follow us on LinkedIn to keep updated with industry events and news as well as to find out about our latest articles, publications, panels and speaking engagements.

Follow us on LinkedIn